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ABSTRACT 
  
Organ-on a-chip technology is becoming a popular method for drug testing. 
Microfluidic Organ-on-a-chip eliminates the need for live objects, such as animals, to do 
drug testing. Although the Organ-on-a-chip devices are becoming popular, creating a 
microfluidic device to represent human placenta is more challenging than other organs. 
Current drug testing methods are considered unethical and unreliable due to drug testing on 
animals and cost. The human placenta is a temporary organ created during pregnancy to 
connect fetus and its mother to allow nutrient supply, gas exchange, waste elimination, and 
avoid internal infections. Researchers wanted to study how the two-way traffic reacts when 
it’s blocked by bacteria/viruses while it transfers the nutrients/ oxygen, since the lack of 
transportation can affect the health of the mother and the fetus. When animal organs are used 
for testing on the human placenta, inconsistent results have been found due to the differences 
among species in physiological functions of human placental barrier, including permeability, 
transport of supplements, patterns of blood flow, and even in metabolic activities. Our 
“Placenta-on-a-chip” device is designed to represent a working placenta organ using human 
cells in order to imitate the nutrient/waste transfer between the maternal blood and fetal 
blood. HUVEC cells (endothelial) and BeWo cells (trophoblast) were used to represent the 
placental barrier with a high concentrated collagen coated membrane. The objective is to 
analyze the glucose transport between the endothelial-trophoblast barrier through the 
membrane. In the future, researchers will have the opportunity to use the placenta-on-a-chip 
model for additional research in drug testing.  
vi 
 
 
Trans-epithelial electrical resistance (TEER) is a useful method to study the 
performance of the cell growth in organ-on-a-chip devices. The latest published reports that 
use this method to find the TEER measurements conclude a large variation in same and 
different cell line studies. The current study was motivated to find an efficient method to 
monitor and study the cell growth in the chip system. Indeed, the transcellular-paracellular 
circuit was used with considerable changes to reduce the large variations shown in literature.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 Placenta 
The human placenta is a temporary organ that is created during pregnancy. The placenta 
connects and separates the mother and the conceptus to allow nutrient and metabolic waste 
transportation, gas exchange, and hormone creation to support pregnancy. The placenta can also 
create hormones to fight against internal infections caused by xenobiotics, bacteria, viruses, and 
parasites. During pregnancy, mother and fetus may interfere with various toxics that could be 
harmful for both mother and fetus.1 Alcohol, drugs, and tobacco use can significantly impact the 
chance of getting chemical compounds which may harmful as well.2 Toxics and chemical 
compounds could cause placental function failures under main functions such as the hormone 
production and release, and nutrient/metabolic waste transport.3 Also, this could affect the 
growth of the conceptus from the prenatal beginning stage to the delivery stage. Substance 
transportation from mother to fetus occurs through a multilayered structure called “placental 
barrier”.4 This two-way transportation of nutrients, oxygen, and metabolic waste could get 
blocked and cause significant damages to the health of both mother and fetus. Even though the 
placenta is supposed to fight against these types of infections, it is clear that interfering 
substances can cross the placental barrier and cause developmental toxicity.  
 
1.2 Placenta-on-a-chip 
Researchers have conducted a wide range of different studies on placental transport 
including in vivo and ex vivo animal models. These animal models provided inconsistent results 
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as well as inaccurate predictions due to differences in physiological functions in human and 
animal models. In some studies, antibiotics and hormones were used to experiment the placental 
transfer in humans.4 This particular type of study is always hard to perform due to the risk of 
exposure to the fetus. This is one of the main reasons as to why the placenta is the least 
understood human organ. Therefore, researchers changed their direction of placenta experiments 
toward the “Organ-on-a chip” technology.  
 
1.3 Trans-epithelial electrical resistance (TEER) 
Trans-epithelial electrical resistance (TEER) is an efficient parameter to monitor and 
study the cell growth in chip systems.5 Previous studies have been conducted using direct current 
(DC) measurements to study the TEER in Organ-on-chip technology. Previous studies conducted 
using this method provide conflicting results; differences are unexplainable when the results are 
compared to conventional Transwell systems with microfluidic systems. Odijk et al.5 provided a 
mathematical model that can be used to measure the TEER between microfluidic chips and 
Transwell cultures. This study was conducted to measure the TEER in two different geometries: 
microfluidics chips and Transwell cultures. In past studies, EVOM2 and a similar Millicell ERS-
2 are used with Ag/AgCl electrodes to measure the TEER. Millicell ERS-2 or similar 
instruments are comparatively expensive and it is something not necessary to purchase for just 
one experiment. In this study, industrial multimeter is used with Ag/AgCl electrodes to make the 
path of conducting under easy and low-cost system to measure the TEER.  
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1.4 Objectives 
The objective of designing a placenta-on-a-chip is to provide a more accurate drug testing 
model to study drug delivery to the placenta. This model will eliminate the need of animal 
models to test drugs. The objective for the TEER experiment is to use a multimeter to measure 
all TEER measurements in the placenta-on-a-chip device. The main goal is to compare the 
results using both theoretical and experimental methods. 
  
1.5 Outline 
A summary of next chapters are as follows:  
Chapter 2: Literature review on different in vivo animal drug testing, ex vivo animal drug testing 
and placenta-on-a-chip designs.  
Chapter 3: Placenta-on-a-chip design factors, final design and fabrication techniques are 
discussed.  
Chapter 4: Cell culturing techniques are discussed in detail. Cell injecting procedure to the chip 
explained.  
Chapter 5: TEER model for both theoretical and experimental methods are discussed.  
Chapter 6: Results for the placenta-on-a-chip is discussed. TEER measurements from both 
theoretical and experimental methods are compared. 
Chapter 7: Conclusions and future work are presented for each experiment.   
 
1.6 References  
1. Myllynen, P., M. Pasanen, et al. (2005). "Human placenta: a human organ for developmental 
toxicology research and biomonitoring." Placenta 26(5): 361-371. 
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CHAPTER 2 
ROAD TO PLACENTA-ON-A-CHIP 
 
2.1 Microfluidics  
Microfluidics is an area of research concerned with the design, manufacture, and 
formulation of engineering fluids at submillimeter scales (microliters or nanoliters). In the 
beginning, microfluidics was used in order to build precisely manipulatable microscale devices. 
Microfluidics was first used in semiconductor industry and later was expanded to micro-
electromechanical systems (MEMS).1 Microfluidic devices are commonly referred to as lab-on-
chip technology.1 Lab-on-chip technology is mainly used for biomedical research purposes. A 
primary goal of current research is to develop microfluidics technology to make the biomedical 
researchers’ work easier than the current status. In the prevailing world, many microfluidic 
devices have been designed to represent the human organ research, but most of the devices failed 
to enhance the capabilities of the full organ. Although most of the microfluidic devices are made 
to represent everyday biomedical research, most of the designed microfluidic devices are still in 
the engineering phase. Any technology can be engineered with an appreciable degree of 
precision and ingenuity, however, identifying suitable application(s) is in itself a challenging 
task.  
Engineers are having difficulties in building working models of microfluidic devices to 
present a micro-scaled function.  So these devices are still in the development phase. 
Microfluidic devices cannot be easily designed by scaling-down a larger device, it requires 
significant modifications to the system. A few important concepts are defined below for 
describing a microfluidic device:  
6 
 
 Laminar versus turbulent flow: In microfluidic devices, the Re (Reynolds number) is in 
the laminar flow regime.  
 Surface and interfacial tension: Liquids have the ability to reduce free energy by 
contracting the surface-air interface.1 This is due to the higher surface tension between 
liquid molecules than between the liquid molecules and air interface. This phenomenon 
can be used to transport fluids through microchannels.  
 Capillary forces: Capillary force or capillary action is often defined as the ability for fluid 
to move without assistance of or opposition from external forces like gravity. Because of 
this ability, tubing and microchannels in microfluidic devices have the ability to flow the 
liquid without any effects of external forces.  
 
2.2 Organ-on-a-chip devices 
Organ-on-chips are microfluidic devices designed to represent the physiological 
functions of tissues and organs by using living cells.2 These chips have the ability to contain cells 
that can be cultured with continuous perfusion inside a micro-sized chamber on the chip 
designed to represent a specific tissue and organ. The simplest design with a single cell layer 
cultured onto a microfluidic flat-form can be developed into a complex microfluidic organ-on-
chip model by using multiple cell layers separated by a membrane (representing the barrier 
between two tissues).  
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2.3 Why is a microfluidic platform appropriate to model an organ? 
Microfluidic platforms used for Organ-on-a-chip applications are compartmentalized, 
thus mimicking organ structure.3 Scaling laws create conditions favorable to mimicking organ-
like environments on the scale in which interactions take place in these compartments. At this 
small scale, the concentration of secreted signaling molecules could reach those found in in 
vivo.4 Furthermore, the confined nature of the compartments allows gradients of soluble 
molecules to be maintained as found in organs in vivo.5 Furthermore, subcompartments could be 
created inside the channel due to laminar flow.  In addition, disease conditions could be 
replicated inside an organ on a microfluidic chip with compartments by varying the fluid flowing 
through.  
  The presence of a number of compartments in the same chip allows it to maintain 
multiple well-regulated chemical and physical culture conditions. This is important in mimicking 
organ function because an organ contains multiple cell types that function separately but 
communicating with each to behave as one integrated system.  Thus, the microfluidic approach 
with separate compartments helps in understanding cellular communication among cells and 
tissues.6,7 The presence of spatially distinct, micro- scale compartments makes it possible to 
culture different representative cell groups under different chemical and physical parameters in 
order to model organ activity. Further, the ability to perform multiple ‘experiments’ on a small 
microfluidic chip makes the process cost effective and takes up less laboratory space. Parameters 
on the microfluidic chip can also be changed using valves to vary the conditions of the same 
structure.8 
Since different tissues in an organ are analogous to different cell types in spatially 
separated compartments, it is possible to find further analogies in comparing tissue-tissue 
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interactions and cell group interactions on the chip. Mass and energy flow between 
compartments can be regulated to vary the soluble molecule and physical force transfer between 
tissues. Once these changes are induced, the resulting behavior of cell groups are observed in a 
device with a small footprint.9  
 Overall, complex organ level interactions can be created on a microfluidic chip. For 
example, the liver microenvironment was recreated in vitro on a PDMS microfluidic chip.10 
 
2.4 Animal related placenta drug testing 
Drug testing using animals can be divided into two categories: in vivo and ex vivo. In 
Latin, in vivo means “within the living” and ex vivo means “out of the living”. In biological 
sciences, in vivo refers to experiments done in animals or humans as a whole organism while ex 
vivo refers to experiments conducted on an actual tissue outside of the whole organism. In ex 
vivo experiments, results are considered more accurate than in vivo experiments, as whole 
organism used in in vivo experiments are partially or completely dead during the experiment due 
to limited control on the living object. But in ex vivo experiments, there is more ability to control 
the conditions to represent the same functionality as the actual organ, but it is considered to be 
more difficult to compare with in vivo experiments. Section 2.4 is focused on in vivo and ex vivo 
placenta related experiments on animals.  
 
2.4.1 In vivo placenta drug testing on animals 
Placental transport was studied mostly using in vivo animal models. In 1977, Pedro Rosso 
conducted his research on “Maternal-Fetal Exchange during Malnutrition in the Rat’’.11 The 
main goal of this study was to monitor placental transfer of “α-amino Isobutyric acid”. Three-day 
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pregnant rats were initially taken and fed with ad libitum (a stock diet) for two days. Rats were 
divided into two groups after the sixth day; an experimental and a control group were fed with 
two different percentages of casein diet. The transfer of α-amino Isobutyric acid was studied on 
day 20 and day 21. One placenta and one fetus from a rat of each group were removed to study 
the transfer of amino acid. Study showed that, the low casein fed rats had a smaller percentage of 
α-amino isobutyric acid in the fetus relative to the high casein fed rats. In another study 
published by Pedro Rosso in 1997, he studied the placental glucose transfer.12 The same 
procedures were performed until day 20 of pregnancy. At day 21 of pregnancy, the rats were 
injected with urethane (200mg/100g of body weight). Then their left femoral vein was injected 
with pyranoside (1µCi/100 g of body weight) and after ten minutes, their right femoral vein was 
also injected with pyranoside (5 1µCi/100 g of body weight). Ten minutes after each pyranoside 
injection, maternal blood samples were taken to determine the glucose percentage. Low casein 
fed rats had a lower glucose percentage in their fetus’ relative to the high casein fed rats.  
Rosso et al. (1981) performed a study to determine the placental blood flow and nutrient 
transfer in different sized pregnant Guinea pigs.13 Different aged guinea pig fetuses were divided 
into three groups relative to the body weight: small, average, and large. The goal of the study 
was to determine the transfer of α-amino isobutyrate and methylglucose with placental blood 
flow in the maternal side. The study concluded that the fetal growth retardation in guinea pigs 
was related to the low placental blood flow and smaller placenta. In this study, the placental mass 
was related to the body weight and three fetal sizes were determined by the body weight of the 
guinea pig dams. Strong correlations were found in α-amino isobutyrate transfer rates and 
smaller fetuses. This suggested that the fetal growth rate also depended on the availability of 
amino acids. In addition, the reduced transfer of α-amino isobutyrate and methylglucose is 
10 
 
relative to the fetal growth retardation in smaller fetus. Persson et al. in 1990 studied glucose and 
amino acid transfer in guinea pigs with intrauterine growth retardation and concluded that the 
reduction of placental blood flow was affected by the transfer of α-amino nitrogen to the fetus.14 
In addition, the intrauterine growth retardation was related to the ‘fetal weight/placental blood 
flow’ ratio. This is found to be a characteristic of human intrauterine growth retardation.15 The 
change of ‘fetal weight/placental blood flow’ ratio is likely due a chromosomal abnormality or 
an intrauterine infection. 
A study was performed by Osgerby et al., 2004 to determine how maternal undernutrition 
affects placental growth.16 Birthweight is correlated with the fetal growth and the placenta grows 
proportionately with the fetus. Ewes were chosen to perform this study because they have a 
cotyledonary placenta in which fetomaternal exchange occurs at discrete locations. This study 
was performed on 48 ewes to determine the effects of maternal undernutrition on placental 
growth. Ewes were left under different nutrient conditions for 45, 90, and 135 days to get the test 
results. The results showed that placental weight on 45 and 90 days, which relatively reduced the 
insulin-like growth factor binding protein.  In addition, the placentome number (number of fetal 
and maternal tissues involved) was found to not be affected by undernutrition or gestational age.  
Another factor for intrauterine growth retardation is the low protein supply to the fetus. 
How the low protein supply affects intrauterine growth was studied by Malandro et al. in 1996 
using rats.17 Researchers have found that the intrauterine growth retardation also affects health 
after birth. A child born from the condition of intrauterine growth retardation has a higher risk of 
interfacing with coronary artery disease, stroke. Another study was performed on amino acid 
transport in the rat placentae of dams maintained with an adequate, low protein calorie diet. 
Maternal, fetal, and placental weights were controlled by the protein supply in amino acid 
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transport’s control. Researchers have found that dams fed with a low-protein isocaloric diet had 
less maternal, fetal, and placental weights compared to dams fed with a 20% casein diet. This 
was mainly due to a decrease in “fetomaternal serum amino acid ratios”. Nutrient transfer to the 
fetus was reduced due to this decrease in fetomaternal serum amino acid level.  
Reid et al. (1999) performed a study to determine the effect of intrauterine growth 
retardation on glucose transporter proteins in rat fetuses with a gestation age of 19 days.18 To 
study glucose transport (glucose transporter protein 1 and glucose transporter protein 2), 
maternal rats were killed and the uteri and fetuses removed. Western blotting and 
immunohistochemical analyses were performed in placental membranes to evaluate the densities 
of glucose transporter protein 1 and glucose transporter protein 2. It was found that intrauterine 
growth retardation had no effect on the amount of fetal glucose transporter protein 1 and glucose 
transporter protein 2 messenger ribonucleic acid. Loutsevitch et al. (2007) performed a study on 
baboons, which showed that moderate maternal nutrient restriction leads to placental 
morphological changes.19 Poor nutrient supply to the fetus can result not only in intrauterine 
growth retardation of the fetus, but also effects on the mother. The basic reasons for poor nutrient 
supply come from the mother’s side, including eating disorders, adolescent pregnancy, and 
nausea. Good fetal growth and good pregnancy outcomes are associated with a well-being of the 
placenta. Due to the similarities on the placenta structure of baboons and humans as well as 
human placentation, baboon models are widely used for placental drug testing. This study 
concluded that the low nutrient supply caused no change on the volumetric structure of the 
placenta, but at the end of the gestation, placental weight decreased without changing the fetal 
weight or length.  
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Coan et al. (2008) conducted a study to investigate how the placental nutrient transfer 
affects the placental efficiency (grams of fetus produced per gram of placenta) in mice.20 The 
major determinant of fetal growth is the nutrient supply, which depends on the size, blood flow, 
and transporter efficiency of the placenta. Most research focused on the effects of reducing 
placental weight demonstrated failures in physiological functions. Human placenta studies have 
linked physiological function failures with disease risk after birth. Coan et al. concluded that the 
lower weight of placenta resulted in higher performance of amino acid transport in the placenta 
with this adaptation increasing age.20 
Coan et al. (2010) performed an investigation on how the placental phenotype supports 
fetal growth in pregnant mice.21 Low birth weight, low life expectancy, and low fetal growth are 
the results of undernutrition during pregnancy. Poor nutrition during prenatal development 
caused low birth weight. One hundred and thirty six virgin female mice were used to perform the 
study. After being housed with males, they were moved to a single house and fed with a low 
nutrition diet. On day three, mice were randomly selected and fed 80% of controlled diet supply. 
Then they were kept in a 12h dark light cycle with free access to water. The results showed that 
the both placental and fetal weights were reduced in the diet-controlled mice.  
 
2.4.2 Ex vivo placental drug testing models on animals 
A research paper published in 1996 by Polliotti et al. group developed an improved 
method for placental lobule long-term perfusion to investigate infection agents such as HIV 
(Human Immunodeficiency Virus) in maternofetal transfer.22 Prior to this study, researchers 
were not able to continue the perfusion for more than 24 hours with fully functional placental 
lobule in order to study how agents were transferred from the maternal circulation. The main 
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problem of tissue contamination was solved with modifications to the perfusion conditions (i.e., 
improvement in oxygenation) including the use of a biohazard hood and an intravenous bag for 
the medium perfused in closed circuit. An oxygenator with Mera Silox-S 0.3 membrane and 
Electromedic Cardioplegia heat exchangers were used to provide more oxygen and a warm 
perfusate before the oxygenation.22 The main parameters compared using this system were 
glucose consumption, lactate production, and hPL (human placental lactogen) production as a 
function of perfusion time. Glucose concentration, lactic acid levels, and hPL in the perfusate 
were measured using a Hitachi 717 analyser, Abbott TDX/FLX analyzer, and ELISA kit 
(Enzyme Linked Immunosorbent assay), respectively.22 Experimentally measured data was 
compared with the theoretically calculated data for each four hour period on a concentration 
basis. To test an infectious agent such as HIV, the experiment was conducted in a laminar flow 
hood with safety precautions, as there is risk to researchers of contamination from the system. It 
was found that the newly introduced oxygenator and heat exchangers provided more temperature 
control and gas exchange and conserved more physiological functions in human placenta. Also, 
because it requires more than 24 hours to examine the course of an infection through a tissue, the 
system allowed testing of infection agents due to its long-term perfusion capability.  
Woo et al. (2012) conducted the first study of how ochratoxin A (OTA) transfers in 
human placenta using perfused human placentae.23 OTA analyses from animal related studies 
and human fetal samples were not yet able to establish how this mycotoxin transfers through 
human placenta because the physiological functions of human placenta differ with growth stages 
of growth and it is not accurate to make predictions from animal related studies due to 
differences between humans and the animal models. OTA transport through freshly obtained 
placentas (from 38-48 week, full term pregnancies) was studied in 4 hour periods. Towards full 
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term the thickness of placental cell layers decreases. Thus, the full-term placenta, with its 
decrease thickness of cell layers, might have allowed higher exposure of toxins to the fetus 
compared with less developed placentae. This study also found that the OTA transfer rate was 
much lower than for other micotoxins transported through the human placenta (ie: aflatoxin and 
Deoxynivalenol).24   
 
2.5 Placenta-on-chips drug testing models 
 
2.5.1 Placental barrier structure  
The following information is based on “Multi-layered placental barrier structure 
integrated with microfluidic channels” by Miura et at. (2013).25 The placenta separates the 
maternal and fetal flow and continuously monitors the substances transferred between maternal 
blood and fetal blood. The placental barrier consists of extracellular matrix and various types of 
cells, membrane matrices (ie: laminin and type IV collagen), and syncytiotrophoblasts. The 
syncytiotrophoblasts are a special type of epithelial cell, which are in direct contact with the 
maternal blood.26  
 
2.5.1.1 Cell culture 
HUVEC cells and BeWo cells were used to represent the endothelial cell layer and 
trophoblastic cell layer, respectively. HUVEC cells were obtained from Lonza and cultured with 
EGM-2 (Lonza) medium to get 5x105 cells. BeWo cells were cultured in an F-12 Hams (Sigma) 
mixture containing 10% fetal bovine serum to get 7x105 cells.  
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2.5.1.2 Chip fabrication and cell deposition 
An SU-8 mold from photolithography was used to fabricate microfluidic channels onto 
the PDMS sheets. Both channels are 2 mm wide by 20 mm long. Two PDMS layers were 
sandwiched with a vitrified collagen membrane in between; the chip was assembled using acrylic 
boards and nuts.  
HUVEC cells were placed onto the collagen vitrigel. After five hours of cell adhesion, 
the chip was flipped and BeWo cells were placed onto the other side of the collagen. After two 
days of cell culture, membrane-like matrices such as laminin and type IV collagen were observed 
and cells were identified using florescent imaging. This study was designed to create a 3D 
multilayered structure representing a basic structural placental barrier.  
 
2.5.2 Placenta-on-a-chip 
The following information is based on “Placenta-on-a-chip: a novel platform to study the 
biology of the human placenta” by Lee et at. (2015).27 This study created a model to represent 
functions of the placenta using microfluidics and microfabrication. Placenta-derived human cells 
were used to recapitulate the functions of placenta organ by proposing a “Placenta-on-a-Chip” 
model, which can represent the perfusion of human trophoblast and human umbilical vein 
endothelial cells. The placental barrier was represented by a thin ECM membrane in vitro 
conditions.                                                      
 
2.5.2.1 Chip fabrication 
 Two PDMS layers were created with a microchannel on each layer, representing the top 
and bottom cell layers using a soft lithography technique. A negative photoresist, spin-coated 
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wafer was baked at 650C for seven minutes and at 900C for 40 minutes. Again the wafer was 
baked at 650C for five minutes and at 900C for 18 minutes, after placing the mask film with 
channel patter while exposing to UV (ultraviolet) light. Unexposed photoresist was removed by 
rinsing the baked layer with the developer solution and isopropyl alcohol. PDMS prepolymer 
was mixed with curing agent at a 10:1 weight ratio, poured onto the channel mold created on the 
silicon wafer, incubated for four hours at 650C, then placed in a vacuum chamber. Fully cured 
PDMS on the mold was separated and cut into a desired shape saving space for the 
microchannel. Collagen type I from BD Biosciences was mixed with an equal amount of distilled 
water and 10x DMEM to a final concentration of 2.43mg ml-1 and final pH of 7.4. Gel was 
dispensed onto the bottom layer channel area and dried overnight at room temperature. Then the 
bottom layer and top layer were assembled after treating with the plasma cleaner. Silicon tubes 
were inserted into the inlets and outlets and the chips were sterilized by UV before cell seeding.   
 
2.5.2.2 Cell seeding  
Vitrified membrane was coated with 40 µg ml-1 fibronectin and 1.5% gelatin solution to 
promote cell adhesion. After JEG-3 and HUVEC reached a cell density of 5 x 106 cells/ml, JEG-
3 was first perfused to the bottom channel and sat inverted in the incubator for two hours. After 
two hours, HUVEC cells were perfused and the chip was incubated for two hours, inverted from 
the previous position. After two hours, medium perfusion was carried-out using a syringe pump 
at 30 µl/hr of volumetric flow rate for each cell layer (DMEM for JEG-3 and EGM-2 for 
HUVECs). Cells were cultured for three days with continuous flow of medium through the 
syringe pump. To study glucose transfer, DMEM was supplemented with 4.5 g/ml glucose and 
introduced to the bottom JEG-3 cell layer. After 68 hours of continuous medium perfusion, the 
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media were collected from the outlets the glucose concentration was measured. The study 
concluded that microfluidic flatform was able to maintain cells alive for at least 68 hours.  
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CHAPTER 3 
CHIP DESIGN AND FABRICATION  
 
3.1 Chip design considerations 
When determining the shape of the channels, three main factors were considered for 
accurate and efficient diffusion through the path: geometry of the cross-section, particle transport 
properties, and curvature of the flow path.   
 
3.1.1 Geometry of the cross-section 
Various shapes were considered when determining the cross-sectional geometry for the 
chip. Sharp et al.1 summarized previous research work for flow through various cross-sectional 
geometries and compared how the Reynolds number (Re) and velocity would affect the flow 
through the channel. Due to the fact that every experiment on various cross-sectional geometries 
is conducted in a different range of Reynolds numbers and with different experimental 
conditions, it was hard to predict a relationship between the friction factor and the Reynolds 
number to compare different geometries. Different experiments with different parameters on the 
same cross-sectional geometry have also given different relationships to different factors. For 
example, in friction factors for different experiments that were conducted on the same cross-
sectional geometry, there were some that followed the microscale predictions, some that gave 
higher values than predicted, and some that gave lower values than predicted. But for some 
parameter ranges, calculated friction factors in the flow of Newtonian fluid for channels with 
circular, rectangular, and trapezoidal cross-sectional shapes have given an agreement with the 
theoretical macroscale predictions. Sharp et al. concluded that parameters from the shape of the 
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cross-section create a relatively weak relationship with the Reynolds number and the velocity 
through the channel. Table 1 shows a summary of the Reynolds number times the friction factor 
(f) and the ratio of maximum fluid velocity (umax) to bulk velocity (uB) for circular, square, and 
rectangular cross-sectional geometries.  
 
3.1.2 Particle transport properties 
Particle transport properties were considered in determining the shape of the path. Bhagat 
et al. 2 conducted an investigation on how microparticles and nanoparticles passive filter in a 
microchannel with rectangular cross-sections. It was found that for solutions with low Reynolds 
numbers (Re < 50), travel through the rectangular cross-section would perform six equilibrium 
positions; three each on the broadest dimensions of the channel cross-section. In rectangular 
cross-sections, higher shear rates on the narrowest dimensions of the channel caused the particles 
Table 1: Cross-sectional geometries of straight microchannel and their 
resistance to the flow 1 
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to move toward the longer channel walls by the resulting higher lift forces. An advantage of the 
rectangular cross-section is that the higher lift forces acting on narrow dimensions result in a 
shorter channel length being required for particle equilibration. According to the recent recorded 
data for channels with square cross-sections, the typical flows in microfluidic devices (Re < 50) 
cause eight stable equilibrium positions 3, 4. This is due to the uniform shear gradient on all four 
sides of the square. In earlier studies, Segre and Silberberg 5, 6 provided a theoretical explanation 
of particle transport through a tube with a circular cross-section. According to Segre and 
Silberberg, uniformly distributed particles travelling through the tube will form a narrow band 
near the channel walls.  
For the rectangular cross-section case, when it performs six stable equilibrium positions 
(three on each side) on the longer channel walls, one side of the longer channel wall interacts 
with the membrane on the design, which separates two channels. It is important to bring particles 
close to the wall next to the membrane, as this will create a higher percentage of the particles 
diffusing from one channel to another through the membrane. The simplicity of the rectangular 
cross-sections with straight side walls and no curves or bends on the walls makes it much easier 
to manufacture the channels. Because of those two reasons, we decided to choose a microchannel 
with a rectangular cross-section for the design.  
 
3.1.3 Curvature of the flow path 
After choosing the shape of the cross-section, it was important to make a decision about 
the curvature of the microchannel. Martel and Toner7 conducted research to determine the effect 
of particle size and the channel curvature on particle migration in a channel with a rectangular 
cross-section. It was discovered that motion of the particles through a channel was controlled by 
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the main velocities caused by Dean Flow. Martel and Toner studied how the curvature of a 
channel controls the particle distribution and analyzed the effects of the curvature ratio on the 
distribution of different sized particles at constant Rec.  They found that with increased curvature 
ratio of the channel the Dean drag to the force equilibrium and shear lift were affected through 
redistribution of the velocity profile.7 
  Unbalanced forces on the particles cause their movement through the channels. The 
position of the particles will depend the on the size of the particles and the curvature of the 
channel. When the channel is straight, particles will remain on the long walls centered to the 
middle of the wall. When the curvature ratio of the channel increases, particles will move toward 
the center of the channel cross-section or to the narrowest geometry of the channel depending on 
the size of the particle. Having a curved channel design is not beneficial because, as the 
curvature increases, particles will start moving off the longer walls of the rectangular cross 
section. This will affect the interaction of the particles with the membrane in the design. When 
the particles are not interacting with one side of the longer wall, where the longer wall interacts 
with the membrane, it will cause a low percentage of the particles diffusing from one channel to 
another channel. It will also be too complicated to manufacture a channel designed to have a 
curvature. Therefore, a straight channel was chosen for the design.   
 
3.2 Final chip design 
Considering all above stated design factors, the chip was designed with straight channels 
and a rectangular cross-section. The two inlets and two outlets are separated with a 1350 angle 
from the mid-section to make sure there is enough space to connect to the tubing (Figure 1a). 
The channel was designed with a width of 400 micron, a height of 10 micron, mid-section length 
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of 10 mm and inlet/outlet diameter of 1 mm. The two channels were separated by a membrane in 
the middle to represent the placental barrier (Figure 1b). Preparation of membrane will be 
discussed in a future section.  
3.3 Chip fabrication  
Microfluidic chips are fabricated using a variety of materials. In this section, fabrication 
of placenta-on-a-chip using PMMA and PDMS is discussed.  
 
 
 
Figure 1: Placenta-on-a-chip channel layout showing (a) aerial view of the top 
and the bottom channels with inlets and outlets, (b) cross-sectional view of the 
middle part of the chip containing two channels centered with the membrane. (not 
to scale) 8.  
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3.3.1 Polymethyl Methacrylate (PMMA) fabrication  
Initially, the placenta-on-a-chip was fabricated using PMMA. PMMA was chosen due to 
its clearness and ability of seeing through a microscope visually. A SolidWorks sketch is shown 
in Figure 2, was created as the first step of the placenta-on-a-chip fabrication.  
A placenta-on-a-chip consists of two layers of PMMA separated by a thin polyester 
(PETE) membrane filter (0.4 micron pore-size; Sterlitech Corporation). The G-code was 
generated using the SolidWorks sketch and the two layers of the chip were milled using a CNC-
Mini Mill-GX (Minitech Machinery).    
Figure 2: SolidWorks sketch of the placenta-on-a-chip for scale. Circles show 
the holes for screws and washers.  
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Each channel of the microfluidic device was designed to have a cross-sectional width of 
400 microns, a cross-sectional height of 100 microns, and a total channel length of 2cm. The 
same G-code was used to make holes for inlets and outlets and hole for the screws on the 
microfluidic device (Figure 3a). Each channel of the chip (Figure 3b) was wiped with alcohol 
swabs for sterilization. Then both layers of the chip and the nuts, bolts, and washers were soaked 
for 20 minutes in a bath in 70% ethanol (Figure 3c).  
1.5 % gelatin solution was prepared by mixing 1.5g of gelatin from porcine skin (Sigma-
Alrich) with 100mL of ddH2O. The solution was autoclaved for 20 minutes and cooled at room 
Figure 3: The complete cycle of PMMA chip fabrication and assembly. (a) The 
PMMA workpiece was milled using the G-Code, (b) each channel on the 
completed PMMA layers was sterilized with ethanol swabs, and (c-f) the two 
layers were assembled with a gelatin-coated PETE membrane in between and 
tubing connected to inlets/outlets 9.  
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temperature until the solution reached room temperature. A 70% ethanol-washed PETE 
membrane piece was placed on the bottom layer of the chip covering the area of the section 
overlapping the top and bottom channels (mid-section). Then the membrane was coated with 20 
µL of prepared 1.5% gelatin solution as shown in Figure 3d (this process was done in a 
biological safety cabinet). The layer with the gelatin coated membrane was incubated for two 
hours before assembling. Two layers were sandwiched together and washers, nuts, and bolts 
were inserted to hold them (Figure 3e). Nuts and bolts were tightened after aligning the top and 
bottom channels with the aid of a microscope. Four small 1/16 ft. diameter PEEK tubes (IDEX 
Health and Science) were inserted to the inlets and outlets and attached to 0.062 x 0.125 inch 
laboratory tubing (DOW Corning) with epoxy glue for a completed device (Figure 3f). 
 
3.3.2 PDMS fabrication  
This section will be focused on the technique used to create PDMS microfluidic devices. 
Soft lithography technique is used to create silicon wafer molds, which will be used as a mold to 
create the microfluidic devices. Then, soft lithography replication is used to create the PDMS 
microfluidic devices using the silicon wafer mold. Section 3.3.2.1 and Section 3.3.2.2 are 
focused on the PDMS soft lithography and PDMS soft lithography replication, respectively.  
 
3.3.2.1 PDMS soft lithography  
Different researchers use different steps for soft lithography to create microfluidic 
devices. In this section, one method of creating a silicon wafer mold using soft lithography 
technique is explained.  
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The first step is to clean a new wafer using piranha solution (H2SO4 + H2O2) or acetone. 
To allow the SU-8 coating to stick better, the wafer is heated for 15 minutes at 1200C. The next 
step is to create a negative photoresist using a spin coating technique. This photoresist layer will 
later be the mold. The Su-8 negative photoresist is created in two steps: low rotational speed and 
acceleration for 10-30 seconds and high rotational speed and acceleration for 30 to 60 seconds to 
Figure 4: Eight step SU-8 mold fabrication process. The SU-8 coating is used for 
silicon wafer substrate. Eight steps are (a) preparation of the wafer, (b) spin 
coating of the negative SU-8 photoresist, (c) first bake the photoresist (soft bake), 
(d)UV exposure, (e) second bake the photoresist (post exposure bake), (f) SU-8 
development, (g) rinse with isopropanol, and (h) third bake the photoresist (hard 
bake) 10.  
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achieve a 100micron thick layer. To make the SU-8 photoresist more solid by evaporating the 
solvent, the wafer goes through the soft baking process. The soft baking process is broken into 
two steps: ten minutes at 650C and 30 minutes at 950C. After the baking process, a photoresist 
edge bead appears around the wafer due to surface tension from baking. To remove the edge 
bead, acetone is injected while the wafer is rotating at a high speed. UV exposure is used to 
initiate the cross linkage by the activation of PhotoActive component in the photoresist 10. A 
layout of the “channels visible” photo mask is placed on the wafer, so that the part that is 
exposed by the UV light (channels) will harden. The exposure wavelength during the SU-8 
hardening is 365 nm and the exposure energy is 480 mJ/cm2.  After the UV exposure, the wafer 
undergoes through the second photoresist bake. This will generate more energy to continue the 
PhotoActive reaction. The baking is done in two steps similar to the soft baking, but for different 
durations: one minute at 650C and ten minutes at 950C, continuously. When the wafer reached 
room temperature, the SU-8 developer solution was used to dissolve the non-linked SU-8 
photoresists. Then the wafer was rinsed using isopropanol and left to dry. Afterwards, the third 
and final baking process was performed, which is an optional step that can prevent future cracks.    
 
3.3.2.2 PDMS lithography replication from SU-8 mold 
Polydimethylsiloxane (PDMS) is a polymer that is widely used to create microfluidic 
devices with SU-8 molds. PDMS is created by mixing a curing agent with PDMS at different 
w/w ratios depending how hard or soft the PDMS needs to be. Once the SU-8 mold was created, 
the PDMS solution was created by mixing the curing agent and the PDMS at 1:10 w/w for this 
research purpose. The created SU-8 mold was placed on a 15 cm diameter petri dish (relatively 
larger than commonly used) and ready to be used as the mold. Well-mixed PDMS was poured 
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into the petri dish containing the master mold and left on a balanced table for at least 24 hours 
before use. Once the PDMS solidified, it was cut around the substrate and peeled off the mold. 
After separating the layers into the designed shape, inlet/outlet holes were made using a puncher. 
To assemble the chip, pre-created vitrified collagen membrane (vitrified collagen membrane 
creation is discussed in next section) was placed on the bottom layer and both top and bottom 
layers were plasma cleaned. Plasma cleaning activates the Si-CH3 surfaces to Si-OH so that, 
when surfaces are pressed against them, a strong and permanent Si-O-Si link is formed. 11 The 
chip was sterilized by leaving it under UV for 20 minutes.  
 
3.3.2.3 Vitrified collagen membrane 
PETE membranes with 0.4 micron diameter pores were obtained from Transwell plates 
with membrane inserts (Corning). Concentrated collagen from rat tail tendon (8.38 mg/mL) was 
obtained from Corning® and mixed with equal amounts of Dulbecco’s MEM (10X) and de-
ionized water to bring the collagen to a final concentration of 2.5 mg/mL. Both sides of PETE 
membranes were coated with the prepared collagen solution and left in the room temperature for 
six hours. Once the collagen dried on the membrane, they were used for the chip assembling 
process.  
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CHAPTER 4 
PLACENTA-ON-A-CHIP 
In this chapter, HUVEC and BeWo cell culturing techniques and placenta-on-a-chip 
testing procedures are discussed. Section 5.1 is focused on the cell culturing. Most parts of the 
processes are followed according to the original manufactures’ protocols (Lonza and ATCC) 1, 2.  
 
4.1 Cell culture 
 
4.1.1 HUVEC cell culturing  
The base medium used for HUVEC cell culturing is EBM-2 (Endothelial Basal Medium) 
from Lonza. EGM-2 (Endothelial cell growth medium) was created by mixing the SingleQuots 
Kit with the basal medium. The SingleQuots Kit contains cytokines, growth factors, and other 
supplements.  
 
4.1.1.1 Starting and maintaining an original HUVEC cell vial 
The original HUVEC cell vials were stored at ~ -2000C in liquid nitrogen. First, 10mL of 
EGM-2 in a T-75 cell culture grade flask was left in an incubator at 370C with 5% CO2 for 20 
minutes. Once the medium in the flask was ready, a cell vial was removed out from the liquid 
nitrogen freezing unit and thawed in a 370C water bath for a few seconds until the ice could be 
barely seen at the bottom of the vial. Then the contents of the vial were transferred into the T-75 
flask and the flask was placed inside the incubator.  
The medium was changed 24 hours after seeding and every 48 hours thereafter. 
Following the HUVEC culture manual in Lonza, the volume of medium depended on the cell 
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confluency in the flask. If the percent of confluency was 45% or higher, the media volume was 
increased by 4-5mL of medium that had been thawed in a 370C water bath for 20 minutes before 
refreshing media. 
 
4.1.1.2 Subculturing HUVEC Cells 
Cells are ready for the subculture once they have reach 70-85% of confluency. 
Trypsin/EDTA solution was used as the dissociation solution. First, old media was removed 
from the T-75 and the attached cells were rinsed with 3 mL of 0.025% (w/v) trypsin in 0.01% 
EDTA solution (Gibco®). Then 2ml of trypsin was introduced and left over the cells and the 
flask left at room temperature for about 15 minutes. Over this time period the flask was observed 
couple of times under the microscope to check for cell detachment. Trypsin should not be left on 
the cells for more than 20 minutes as it can destroy them. Once most of the cells were detached 
the trypsin solution containing the cells was placed into a 15mL conical tube that was then filled 
with EGM-2 up to 10mL. The cells were centrifuged at 200 x g for five minutes and the medium 
was removed from the conical tube. The pellet was used for freezing the cells or their subculture. 
Since the cells are really expensive, it is important keep a backup storage of frozen cells for 
future use. The most important part of the freezing the cells is the composition of the freezing 
medium. For most cell types the freezing medium contains 10% DMSO (dimethyl sulfoxide) and 
90% complete medium. For HUVECs, it is 10% DMSO and 90% of EGM-2. To freeze cells in a 
pellet, about 3mL of EGM-2, 10% DMSO was added to the conical tube and medium was mixed 
with the pellet using a micropipette. One milliliter was transferred to each cryovial, which were 
left overnight in a -800C freezer and then transferred to liquid nitrogen storage.  
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Cells were subcultured at a dilution ratio of 1:3 as follows. 10mL of EGM-2 was 
transferred to a T-75 flask and incubated for 20 minutes. Once the medium was ready, equal 
amounts of the cells mixed with EGM-2 were transferred to three T-75 flasks, and the same 
medium refreshing procedures were followed as discussed in Section 4.1.1.1.  
 
4.1.2 BeWo cell culturing 
The base medium used for BeWo cell culturing was F-12K medium (Kaighn’s 
Modification of Ham’s F-12 Medium) from ATCC®. The complete growth medium was created 
by adding 10% of FBS (Fetal Bovine Serum) from ATCC® from the total volume of base 
medium (F-12K).   
 
4.1.2.1 Starting and maintaining an original BeWo cell vial 
A T-75 cell culture grade flask was filled with 10 mL of F-12K growth medium and 
incubated for 20 minutes at 370C and 5% CO2. The original BeWo cell vial was removed from 
the ~-2000C liquid nitrogen freezing unit and thawed in a 370C water bath for a few seconds until 
the ice at the bottom of the vial could barely be seen. Once the flask with medium was ready, 
cells from the vial were transferred to the flask using a micropipette. The flask was incubated for 
24 hours.  
After 24 hours of seeding, the flask was observed under the microscope to see if the cells 
were at 45% or higher of confluency. Then the flask was refreshed with F-12K growth medium 
and every 48 hours thereafter. The refreshing volume of the F-12K growth medium was 
increased by 3-4 mL, depending on the percent of confluency increase rate.  
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4.1.2.2 Subculturing BeWo Cells 
Once the cells were at 70-85% of confluency, subculturing was performed following 
ATCC® protocols for BeWo cells. Firstly, the current medium in the flask was removed and 
discarded and the cell layer was rinsed with 3 mL of 0.025% (w/v) trypsin in 0.01% EDTA 
solution to remove all vestiges of serum from the flask. Trypsin EDTA solution (2-3 mL) was 
added to the flask and the cells observed under the microscope for 5-15 minutes until they were 
dissociated. As discussed in Section 4.1.1.2, trypsin should not be kept for more than the 
recommended time (15 minutes maximum for BeWo cells), as it will destroy the cells with 
extended period of time. Once most of the cells were detached, the harvested cells were 
transferred to a conical tube and filled with F-12K growth medium up to 10mL in total. Cells 
were then centrifuged at 250 x g for five minutes. Afterwards, medium was removed from the 
tube carefully and the pellet was mixed with about 30 mL of F-12K (if subculturing) or 3 mL of 
freezing medium (if freezing). As discussed in Section 4.1.1.2, the user has the choice of freezing 
cells or subculturing cells. Freezing medium was created using 5% of DMSO and 95% of F-12K 
growth medium. The same procedures were followed for cell freezing and subculturing, as 
discussed in Section 4.1.1.2.   
 
4.2 Placenta-on-a-chip testing procedures 
Placenta-on-a-chip testing procedures consisted of five main steps: staining cells, 
harvesting cells, controlling cell density, introducing cell lines, and maintaining cell lines in the 
channels.  
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4.2.1 Cell staining 
Cell staining is a technique used to identify cells or cell components on a substratum. 
This section is focused on using CellTrackerTM staining for both cell types: HUVEC and BeWo. 
Information is based on the CellTrackerTM protocol for fluorescent probes 3. For this experiment, 
CellTrackerTM Green CMFDA and CellTrackerTM Orange CMFDA (Life Technologies) short-
term dyes were used for HUVEC and BeWo cells, respectively.  
Firstly, the CellTrackerTM fluorescent probe was allowed to warm to room temperature. 
Then the probe was diluted in DMSO (ATCC) to a final concentration of 10 mM. DMSO (10.76 
µL and 9.08 µL, respectively) was added to HUVEC cells and BeWo cells. Afterwards, the 
Figure 5: Procedure to use CellTrackerTM cell staining dyes 
for both HUVEC and BeWo cells. (a) Allow CellTracker to 
warm to room temperature, (b) dilute in DMSO and serum-
free medium to a final concentration of 0.5-25 µM, (c) 
refresh the flask with pre-created CellTracker solution and 
incubate it for 15-45 minutes, and (d) refresh the flask with 
growth medium.  
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solution was diluted in a serum-free medium (base medium) to a final working concentration of 
0.5-25 µM. It was calculated that CellTracker Green for HUVEC could be diluted in 4 – 214 mL 
of EBM and CellTracker Orange could be diluted in 3 – 182 mL of F-12K base medium. 
CellTracker working solution was then warmed to 370C, which was subsequently used as a 
replacement for the growth medium. The flasks were incubated for 15-45 minutes (depending on 
the cell type) while containing CellTracker working solution. After incubation, CellTracker 
solution was removed and replaced with growth medium. The process of cell staining is shown 
in Figure 5.  
Cells may take longer than 45 minutes to display some results, so it is better to incubate 
for another couple of hours before harvesting cells. Cell harvesting is discussed in the next 
section.  
 
4.2.2 Harvesting cells 
Cell harvesting from a T-75 flask is discussed in Section 4.1.1.2 in detail. Figure 6 shows 
specific procedures of cell harvesting for the purpose of cell introduction to the placenta-on-a-
chip. As discussed in previous section, a cell pellet was obtained after centrifuging. Depending 
on the size of the pellet, 100-300 µL of growth medium was introduced to the conical tube and 
mixed well with the cells by resuspending from a micropipette, then it was transferred to a 
cryovial. The amount of growth medium transferred to the conical tube is important, as a higher 
volume of growth medium mixed with a smaller pellet may result in too low a cell density. 
Procedures of controlling the cell density is discussed in next section.  
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4.2.3 Controlling cell density  
It is important to make sure the suspended densities of both cell types are 5 x 106 
cells/mL before being introduced to the chip. It was always assumed that the suspended cell 
density, which is determined by the volume of growth medium added to the cell pellet, should be 
higher than required. If the measured suspended cell density (as discussed in this section) is 
lower than 5 x 106 cells/mL, the cells should be centrifuged again and resuspended in a smaller 
Figure 6: Procedures for cell harvesting, (a) remove old 
medium and rinse the cell layer with 3mL of trypsin/EDTA 
solution. Introduce 2-3 mL of trypsin and allow for cell 
detachment, (b) after 15-20 minutes (depends on the cell type) 
transfer content to 15mL conical tube and fill with growth 
medium up to 10mL in total, (c) centrifuge for 5 min, (d) 
remove the medium, and (e) Add 200µL of medium and 
transfer into a cryovial. *The centrifuge is run at 200 x g and 
250 x g for HUVEC and BeWo cells, respectively. The volume 
of medium for resuspension can be changed depending on the 
size of the pellet.    
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volume of growth medium. Assuming 200 µL of growth medium was mixed with the pellet, 10 
µL of well mixed cells plus medium was transferred to a cryovial. Then 40 µL of trypan blue 
solution (Gibco) was added and well mixed until the cells were uniformly suspended. Ten µL of 
cell suspension was introduced into a grid on one side of a hemocytometer (LW Scientific) and 
observed under the microscope. An image of the middle portion of a large square on the grid is 
shown in Figure 7.  
A hemocytometer is a counting chamber used to determine cell density. Usually, 
hemocytometers consist of two main grids, containing nine squares each. The central square 
consists of 25 larger squares and each large square is divided into 16 smaller squares. Trypan 
blue solution is an exclusion staining dye used to identify dead cells. When mixed with trypan 
blue, dead cells appear blue. Once the cells were counted on the central square, the following 
equation was used to calculate the density of live cells in the suspension.  
𝑇𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 [
𝑐𝑒𝑙𝑙𝑠
𝑚𝐿
] = 𝑇𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑 ×
𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
# 𝑜𝑓 𝑠𝑞𝑢𝑎𝑟𝑒𝑠
× 10,000 [
𝑐𝑒𝑙𝑙𝑠
𝑚𝐿
] 
Figure 7: Cells mixed with Trypan Blue solution on Hemocytometer.4   
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After finding the density of suspended cells, the following equation was used to convert the 
current cell density to a desired suspended cell density.  
𝑉1
𝑉2
=
𝜌1
𝜌2
 
Where V1 and V2 are the initial volume of the solution and the volume needed to add to the 
solution to get the desired cell density, respectively. ρ1 is the initial cell density and ρ2 is the 
desired cell density. Once the suspended cell densities are adjusted to 5 ×106 cells/mL, the cells 
are ready to be introduced to the chip.  
 
4.2.4 Introducing and maintaining cells on the chip 
PDMS chips created using the soft lithography replication technique (as described in 
Chapter 3) were sterilized under UV irradiation for 20 minutes. The HUVEC cells were injected 
to the top channel of an inverted chip using a micropipette and the chip was placed on a petri 
dish with a lid. Two to three small caps filled with autoclaved deionized-water were placed on 
the petri dish to provide humidity and control evaporation. The chip was incubated for 12 hours 
to allow for cell adhesion. After 12 hours, the chip was inverted and the BeWo cells were 
injected to the bottom channel of the chip and the chip was incubated for another 12 hours to 
allow cell adhesion. The evaporation was controlled by leaving EGM-2 and F-12K growth 
medium bubbles on top channel inlet/outlet holes and bottom channel inlet/outlet holes, 
respectively. After 24 hours of cell adhesion in total, the channels were observed under a 
microscope. Fluorescent images were taken following the ZEISS microscope protocols.  
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After fluorescent imaging, four small (1/16 ft. diam.) sterile PEEK tubes (IDEX Health 
and Science) were inserted into inlets and outlets and connected to a 0.062 x 0.125 inch 
laboratory tubing (DOW Corning). Then the inlet tubes were connected to 3mL syringes 
(Becton, Dickinson and Company) that were connected to a syringe pump (Kent Scientific). 
Outlet tubes were sent to a waste container consisting of 10 mM CaCl2 (calcium chloride) when 
the set-up was running inside an incubator or 70% ethanol when the set-up was running outside 
an incubator. The microfluidic cultures were perfused at a constant volumetric flow rate of 
1µL/min driven by 3 mL syringes filled with respective growth medium for each cell type. The 
schematic of this set-up is shown in Figure 8.  
Figure 8: Channel inlets connected to a syringe pump running at a constant 
volumetric flow-rate. Outlets were fed into a calcium chloride solution to kill 
cells.    
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CHAPTER 5 
TRANSEPITHELIAL/TRANSENDOTHELIAL ELECTRICAL RESISTANCE (TEER) 
IN MICROFLUDIC DEVICES 
 
5.1 Introduction 
TEER measurements (Transepithelial/ Transendothelial Electrical Resistance) are used as 
a quantitative method to monitor and describe the quality of the barrier function in epithelial and 
endothelial monolayers.1 In microfluidic systems, TEER measurement conditions are different 
than for Transwell cultures due to three main reasons: smaller cell layer (only on the membrane 
of the chips), higher resistance due to the length of the channel, and different measurements 
depending on the method used.5 Depending on the location of electrodes that measure the 
resistance along the membrane, the accuracy of the data can vary. When epithelial and 
endothelial cells are cultured to form a monolayer, they form tight intercellular junctions. These 
tight junctions can prevent free passage of ions and molecules through the intercellular space of a 
cell monolayer. The presence of tight junctions is characteristic of healthy, confluent monolayers 
of epithelial and endothelial cells. Various methods are described in the literature for making 
electrical measurements in chip devices. These include flow cytometry, patch clamping, 
electrophoresis and electrochemical detection.6,7,8,9  
Cheung et al. (2005) conducted research to identify how flow cytometry can be used to 
characterize the cell population in a microfluidic channel.6 In this study, the group used a 
“microfabricated impedance spectroscopy flow cytometer”, where impedance was used to 
provide data such as size of cells, capacitance of membrane, and conductivity of cytoplasm. All 
the data was obtained as a function of frequency from dielectric measurements. One advantage 
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of using flow cytometry to distinguish cell populations is that it eliminates the need of externally 
added cell markers. Normally, in flow cytometry, cell separation is done by FACS (fluorescence 
activated cell sorting) or a DEP cross-over frequency-based (dielectrophoresis) technique, where 
at the frequency, the particles undergo zero dielectrophoresis force.10 The “microfabricated 
impedance spectroscopy flow cytometer” is cost effective compared with DEP and FACS.6 After 
analyzing the fabricated chips (platinum electrodes coated on two glass substrates) using 
microfabricated flow cytometer, it was found that the proposed method can be used to determine 
the properties of the membrane on which the cells are grown.6  
Pantoja et al. (2004) used patch-clamp electrodes to analyze the macroscopic ion channel 
protein activities on a wafer-based microfluidic device.7 The patch-clamping technique was 
invented to study ion channels and the effects of changing their physical and chemical 
surroundings. The original method of patch-clamping was done by using a 1-2 micron diameter 
pipette11, but this method cannot be applied to a microfluidic system. To overcome this problem, 
Pantoja et al. proposed a wafer-based patch-clamping device to replace the traditional glass 
pipettes. In this study, they focused on the flow of the cells because, aligning the cells in the 
channel would allow them to analyze the macroscopic ion channel activities. They compared the 
results obtained with a traditional patch-clamped device with their proposed method and 
concluded that their method gave similar results to those obtained with the tradition patch-
clamping method. They were able to record the current for 60% of any given cell type, but HIT-
T15 cells were found to be the best compared to other cells used.7 In summary, this group 
successfully made patch-clamping measurements using a microfluidic device connected to a 
voltage clamp setup to determine ion channel activities, as well and the conductance across cells 
attached to the voltage clamped membrane.  
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Lagally et al. (2000) conducted a study on protein and DNA separation by 
electrophoresis.8 They created a microfluidic device capable of PCR (polymerase chain reaction) 
amplification of DNA. Their design allowed transfer of a small volume through the system and 
eliminated the need of manual load for the sample, which resulted in air bubbles during loading. 
Also, it eliminated the risk of contamination from the outside environment. They were able to 
produce 5-6 DNA copies before amplification. This was done by using fluorescent dye to detect 
the amplified product resulting from PCR amplification of only 20 DNA template 
copies/microliter. This method is considered to be more cost and time efficient than current 
methods.  
These different techniques described in the literature require deposition of electrodes to 
analyze or monitor the quality of barrier function. An electrode deposition on substrates such as 
PDMS may result in low oxygen and carbon dioxide in the channels.9 The limitation of oxygen 
and carbon dioxide may result in poor cell growth inside the system. Our chip is not designed to 
deposit electrodes. Therefore, the methods discussed above would not be beneficial. Also, 
depositing electrodes could cause serious damages to the chip, as well as PDMS chips loss in 
flexibility. Having electrodes above the membrane or in the area of the channel will affect the 
flow of the culture medium. Instead, a having electrodes inserted to the inlet/outlet will eliminate 
the need of touching the central membrane as well as limit damage to the cell layers.  
 
5.2 Theory behind the TEER measurements 
Two pathways are responsible for ion and molecular transport in cell monolayer: the 
transcellular pathway and the paracellular aqueous pathway. The transcellular pathway is the 
route that substance can pass through the cells 2. This pathway describes the substances that pass 
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through an epithelial cell layer. The paracellular pathway describes the route that substances can 
pass between the cells 3. This includes substances passing through cell junctions as well as 
intercellular spaces 4. In younger cell cultures, the paracellular pathway plays a larger role in 
TEER than the transcellular pathway, as the adhesion of the cells are not strong and cells have 
not yet formed tight junctions. In this study, the endothelial cell barrier (tissue barrier) is 
substituted with a simple circuit, with resistors that represent the charge carried by the substances 
passing through each pathway as shown in Figure 9. In Figure 9, the sum of Ra and Rb 
represents the transcellular pathway, where Ra and Rb are the apical cell membrane and 
basolateral cell membrane resistances, respectively. The sum of Rtj and Ric represents the 
paracellular pathway, where Ric and Rtj are the intercellular resistances and the tight junction 
resistances, respectively. Ra substances have a chance of travelling through the gap between the 
transcellular and paracellular pathways instead of travelling through both pathways. Rgap 
represents the partial coverage of the cell support, which includes only the membrane resistance 
Figure 9: Simple circuit representing an endothelial cell layer forming a 
barrier, original image based on Abbott et al 1, 5. Reproduced from Odijk et al. 1 
with permission of The Royal Society of Chemistry. 
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because the Rgap is developed as it is parallel to the transcellular and paracellular pathways. The 
simple circuit shown in Figure 9 can be solved by taking the equivalent resistance of the 
resistors in transcellular and paracellular pathways, as two sets of resistors in parallel.   
                               𝑇𝑇𝐸𝐸𝑅 =
(𝑅𝑎+𝑅𝑏).(𝑅𝑖𝑐+𝑅𝑡𝑗)
(𝑅𝑎+𝑅𝑏)+(𝑅𝑖𝑐+𝑅𝑡𝑗)
                                                   (1)   1 
TEER measurements for the placenta-on-a-chip were calculated by two methods: theoretical and 
experimental. The next two sections describe both methods in detail. The purpose of having a 
theoretical method is to validate the results from experimental method.  
 
5.3 Theoretical method  
To build a theory for TEER measurements that explains the geometry and the behavior of 
the cell lines in channels, the placenta-on-a-chip is simplified with two parallel channels 
separated by a membrane.  A simplified equivalent circuit is built by replacing resistors for the 
top channel, bottom channel, and membrane. In Figure 10, the top channel is represented by 
resistors Ra to Rd, including the resistance of the top channel above the membrane area, which is 
indicated as RT1→RTn-1. Similarly, resistance of the bottom channel is represented by the 
resistors Rc to Rb including the resistance of the bottom channel below the membrane, which is 
depicted as RB1→RBn-1. Resistance of the membrane, top channel above the membrane, and 
bottom channel below the membrane are calculated assuming the resistors on that specific area 
are distributed uniformly.  
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According to the above assumption, the calculation is simplified as  𝑅𝑇1 = 𝑅𝑇2 = ⋯ =
𝑅𝑇𝑛−1 𝑎𝑛𝑑 𝑅𝐵1 = 𝑅𝐵2 = ⋯ = 𝑅𝐵𝑛−1 for top channel and bottom channel, respectively. The 
resistance of the channels above and below the membrane is equal to the reciprocal of the 
conductance of each channel over the length of the membrane 1. Equation 2 can be used to 
calculate total resistance of each channel above and below the membrane. In Equation 2, lmem, 
wch, and hch represent the length of the channel above/below the membrane, width of the channel, 
and height of the channel in meters, respectively. K is the conductivity of the cell medium (S m-
Figure 10: Chip simplified to build the equivalent circuit, (a) layout of 
the chip, (b) circuit with resistors substituted for top channel, bottom 
channel and membrane. Reproduced from Odijk et al. 1 with permission 
of The Royal Society of Chemistry.  
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1) and n is the number of resistors on the area. Typically, 1000 resistors are ideal for the 
experiments to get more accurate results.  
                                    𝑅𝑋 =
𝑙𝑚𝑒𝑚
𝑛.𝑤𝑐ℎ.ℎ𝑐ℎ.𝐾
                                                              (2)1 
RM to RMn-1 resistors represent the membrane resistivity, which can be calculated using Equation 
3. RTEER is the TEER measurement taken under more ideal systems like with Transwell inserts, 
which can be found in literature.  P is the porosity of the membrane (%) and hmem is the thickness 
of the membrane. First and second terms represent the resistance due to cell support and 
resistance from the cell barrier, respectively.  
                                         𝑅𝑀𝑥 =
ℎ𝑚𝑒𝑚
𝑃.𝑤𝑐ℎ.
𝑙𝑚𝑒𝑚
𝑛
.𝐾
+
𝑅𝑇𝐸𝐸𝑅
𝑤𝑐ℎ.
𝑙𝑚𝑒𝑚
𝑛
                              (3)1 
Looking at the proposed circuit, theoretical resistance for 𝑅𝑎−𝑏can be solved assuming n 
(number of resistors) approaches infinity. Following this, the two port system can be solved 
assuming the circuit consist of n section of simplified circuit denoted in 𝑉𝐴, 𝑉𝐴
′, 𝑉𝐶
′  𝑎𝑛𝑑 𝑉𝐶 in 
Figure 11.  
Figure 11: Circuit simplified to show the ladder system, original 
figure was taken from supplementary materials of Odijk et al. 
Reproduced from Odijk et al. 1 with permission of The Royal 
Society of Chemistry. 
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Following solution is reproduced from Odijk et al.1 with permission of The Royal Society of 
Chemistry.  
Three new variables are introduced as 𝑅𝑚, 𝑅𝑡  𝑎𝑛𝑑 𝑅𝑏 where, 
 
𝑅𝑚 = 𝑅𝑀 ∙ 𝑛                                               (4)
1 
𝑅𝑡 =
𝑅𝑇
𝑛
                                                      (5)1 
𝑅𝑏 =
𝑅𝐵
𝑛
                                                     (6)1 
The circuit shown in Figure 11, is a ladder network. By applying Kirchhoff’s voltage law 
(KVL), 
𝑉𝐴
′ = 𝑉𝐴 − 𝑅𝑡 ∙ 𝑖𝐴                                   (7)
1 
𝑉𝐶
′ = 𝑉𝐶 − 𝑅𝑏 ∙ 𝑖𝐶                                   (8)
1 
Applying Kirchhoff’s current law (KCL),  
𝑖𝐴
′ = 𝑖𝐴 −
𝑉𝐴
′ − 𝑉𝐶
′
𝑅𝑚
                                    (9.1)1 
𝑖𝐶
′ = 𝑖𝐶 +
𝑉𝐴
′ − 𝑉𝐶
′
𝑅𝑚
                                   (10.1)1 
Simplifying KCL equations using KVL equation,  
𝑖𝐴
′ = 𝑖𝐴 −
𝑉𝐴 − 𝑉𝐶 − 𝑅𝑡 ∙ 𝑖𝐴 + 𝑅𝑏 ∙ 𝑖𝑐
𝑅𝑚
        (9.2)1 
𝑖𝐶
′ = 𝑖𝐶 +
𝑉𝐴 − 𝑉𝐶 − 𝑅𝑡 ∙ 𝑖𝐴 + 𝑅𝑏 ∙ 𝑖𝑐
𝑅𝑚
        (10.2)1  
For one section,      
[
 
 
 
 
iA
′
iC
′
VA
′
VC
′]
 
 
 
 
=
[
 
 
 
 
 1 +
Rt
Rm
⁄
−
Rt
Rm
⁄
−Rt
0
       
−
Rb
Rm
⁄
1 +
Rb
Rm
⁄
0
−Rb
      
−1
Rm
⁄
1
Rm
⁄
1
0
      
1
Rm
⁄
−1 Rm
⁄
0
1 ]
 
 
 
 
 
[
iA
iC
VA
VC
]      (11)1 
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For n sections and n→∞ (n = 1000 assumed to be large enough to get convergent results.) 
[
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0
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−
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⁄
−RT
0
       
−
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⁄
1
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⁄
0
0
      
1
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⁄
−1 RM
⁄
0
0 ]
 
 
 
 
 
]
 
 
 
 
 
n
[
iA
iC
VA
VC
]      (12.2)           
Note that when n→∞,  
𝑙𝑖𝑚
𝑛→∞
(
𝑅𝑇
𝑛𝑅𝑀
)
𝑛
→ 0 
Similarly, when n→∞, 
−𝑅𝐵
𝑛𝑅𝑀
,
−𝑅𝑇
𝑛𝑅𝑀
,
𝑅𝐵
𝑛𝑅𝑀
 → 0  
Now compare the above equation with the well-known identity, 
𝑒𝐴 = lim
𝑛→∞
(𝐼 +
1
𝑛
𝐴)
𝑛
                                                              (13) 
Additionally,  
𝑖𝐴
∞ = 𝑖𝐷 , 𝑖𝐶
∞ = 𝑖𝐵, 𝑉𝐴
∞ = 𝑉𝐷 𝑎𝑛𝑑 𝑉𝐶
∞ = 𝑉𝐵             
Using above values, results can be simplified to: 
[
iD
iB
VD
VB
] = exp
[
 
 
 
 0
0
−RT
0
       
0
0
0
−RB
      
−1
RM
⁄
1
RM
⁄
0
0
      
1
RM
⁄
−1 RM
⁄
0
0 ]
 
 
 
 
[
iA
iC
VA
VC
]     (14)1  
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Assume,  
exp
[
 
 
 
 0
0
−RT
0
       
0
0
0
−RB
      
−1
RM
⁄
1
RM
⁄
0
0
      
1
RM
⁄
−1 RM
⁄
0
0 ]
 
 
 
 
= [
Z11
Z21
Z31
𝐙𝟒𝟏
       
Z12
Z22
Z32
Z42
      
Z13
Z23
Z33
Z43
      
Z14
Z24
Z34
Z44
]             (15) 
This final equation is equivalent to hybrid parameter matrix model for a two port circuit. We are 
interested in resistance between Ports A and B, assuming an input current iA into port “A” (ie: 
Term of our interest is 
𝑉𝐵
𝑖𝐴
⁄ = resistance between Port A & B).  
From the matrix equation above,  
𝑉𝐵
𝑖𝐴
⁄ = 𝑍41                                                 (16) 
Note: In two port circuit theory, when two hybrid parameters are used: 
𝑍41 =
𝑉𝐵
𝑖𝐴
|
𝑖𝐶=𝑉𝐴=𝑉𝐶=0
                              (17) 
By applying calculated values for 𝑅𝑇 , 𝑅𝐵  𝑎𝑛𝑑 𝑅𝑀 from Equation 2 and Equation 3 to Equation 
15, 𝑅𝑎−𝑏 can be solved. The theoretical TEER value can be calculated by multiplying the 𝑅𝑎−𝑏  
value by the membrane area (𝑤 × 𝑙).  
 
5.4 Experimental method 
A simple TEER measuring instrument was built by connecting two 0.5mm x 0.6mm x 
13mm Silver Chloride (Ag/AgCl) electrodes (DOCXS Biomedical) to a digital LCD multimeter 
(Sinometer MS8261) by using regular multimeter probe cables, as shown in Figure 12. Then two 
Ag/AgCl electrodes were connected to the end of two multimeter probe cables.  
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As shown in the Figure 13, one of the Ag/AgCl electrode was inserted into the inlet of the top 
channel, and other electrode was inserted into the outlet of the bottom channel. Then the 
resistance value was read from the multimeter. The resistance value read before growing any 
cells on channels by using the same inlet and outlet to use as the reference resistivity, which 
noted as Rblank in Equation 16.  
𝑅𝑎𝑝𝑝,𝑇𝐸𝐸𝑅 = (𝑅𝑐𝑒𝑙𝑙𝑠 − 𝑅𝑏𝑙𝑎𝑛𝑘).𝑤𝑐ℎ. 𝑙𝑚𝑒𝑚                 (16)
1 
Equation 16 was used to calculate the apparent TEER (the parameter most of the research 
papers used to report the TEER in oragn-on-chips devices), which used the measured resistance 
between two electrodes (Rcells) and subtracted the resistance value measured from the empty chip 
(Rblank), then multiplied the resultant value with the total membrane area (𝑤𝑐ℎ. 𝑙𝑚𝑒𝑚). 
 
 
 
 
Figure 12: Schematic of the experiment setup, Ag/AgCl electrodes connected 
to digital LCD multimeter (Sinometer MS8261) with probes. Original setup 
is used in Pemathilaka et al.12  
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Figure 13: Placenta-on-a-Chip with Ag/AgCl electrodes 
inserted to the inlet of the top channel and outlet of the 
bottom channel. 
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CHAPTER 6 
RESULTS AND DISCUSSION  
Chapter 6 is focused on results and discussion for both placenta-on-a-chip model and 
TEER measurements.  
6.1 Placenta-on-a-chip 
As described in Chapter 4, HUVEC and BeWo cells were cultured until they reached to 
high density. Cells cultivated in low densities may result in low cell density inside the placenta-
on-a-chip. Figure 14 shows cultivated HUVEC and BeWo cells at a high density.  
Figure 14: Cell at high density, captured from ZEISS microscope, 
(a) BeWo cells, (b) HUVEC cells at 50 micron scale (10X).  
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During HUVEC cell culture, it was observed that HUVEC cells tend to attach to each 
other at higher densities. BeWo tended to grow into 3D structures at higher densities. This was 
observed in a different microscope. When performing the fluorescent imaging for HUVEC cells, 
we found that, in addition to staining the cells, the CellTracker stained other material on the 
surface of the flask. Figure 15 shows the BeWo flask after fluorescent imaging.  
 
Figure 15: A fluorescent image of BeWo cells after 45 minutes 
incubation with CellTrackerTM Orange CMRA fluorescent dye. 
The image was taken with a ZEISS microscope 10X.  
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6.1.1 Cells inside the channels after adhesion period 
As described in Chapter 4, green CMFDA fluorescent-stained HUVEC cells were 
injected to the top channel and incubated for 12 hours to help cell adhesion. Figure 16 shows a 
fluorescent image of the chip after 12 hours.  
A major problem with the HUVEC cells was, even when the suspended density was 
adjusted to 5×106 cells/mL, the membrane area of the top channel contained a low cell density. 
This was because most of the cells remained in space between the inlet side membrane end and 
inlet. To minimize this problem, cells were resuspended before taking them up with the 
Figure 16: HUVEC cells in the top channel of the placenta-on-
a-chip after 12hrs of adhesion period, 10X-ZEISS microscope. 
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micropipette tip. However, this adjustment did not change the ultimate cell distribution. After the 
12 hour period of the HUVEC cell adhesion, orange CMFDA fluorescent-stained BeWo cells 
were injected into the bottom channel. Following the same procedures, top and bottom channels 
were observed by fluorescent imaging. Figure 17 shows a fluorescent image of the channels 
with both HUVEC and BeWo cells after 12 hours of cell adhesion for BeWo, and 24 hours of 
cell adhesion for HUVEC cells.  
There is a clear indication from the GFP that most HUVEC cells are located toward the 
edges of the channel. This may be due to two major reasons. First, while we kept the BeWo cells 
on the chip for 12 hours, HUVEC cells were inside the chip for 24 hours. The second reason is 
HUVEC cells did not attach to the membrane, so they were able to move freely. The main result, 
if they did not attach to the membrane, is that those at the edges of the channel will be pushed 
Figure 17: Fluorescent image showing both HUVEC and BeWo cells 
inside the channels after 12 hours of BeWo adhesion. (t=24hours) 
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out from the outlet when perfusion started. Some of the unattached cells could be observed under 
the microscope due to their motion.  
 
6.1.2 Cells inside the channels during perfusion  
After the adhesion period, medium perfusion was started. As described in Chapter 4, the 
medium (EGM and F-12K) filled 3mL syringes were attached to a syringe pump. The syringe 
pump was operated at different flow rates for various trials, but the minimum flow rate 
(1µL/minute) the syringe pump could handle was chosen for the best results. Faster flow rates 
could cause cells to peel off from the membrane while slower flow rates will not follow the 
microfluidic flat form theory of representing an organ and also the same medium will be over the 
Figure 18: Fluorescent image showing both HUVEC and BeWo cells inside 
the channels after 24hours of medium perfusion. (t=48hours) 
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cells for a long period. After 24 hours of medium perfusion, the chip was sent for fluorescent 
imaging. 
As shown is Figure 18, fewer cells were identified in both channels than before 
perfusion. This may be due to the unattached cells observed before perfusion having been pushed 
out from the channels. Also, it was seen that a few air bubbles had developed inside the channels. 
Air bubbles build higher shear stresses on the surface, and this may be another main reason most 
of the cells (even the attached cells) were removed from the channels. The Microscopic 
brightfield image shows floating cells (middle dark spots). This was more visible under the 
Figure 19: Fluorescent image showing both HUVEC and BeWo cells inside 
the channels after 48hours of medium perfusion. (t=72hours), different 
position of the channel from Figure 5.  
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microscope live image, rather than on the fluorescent image due to their motion.  
After 48 hours of perfusion, the same position of the chip observed in Figure 18 
contained no cells (Figure 19). Most of the HUVEC cells had moved toward the edges of the 
channel. It was not confirmed if these cells were attached, but the apparent attachment could be 
due to imperfect alignment of the channels during manufacturing process, which could create a 
sharp edge on the channel that could prevent unattached cells from pushing off.  In another 
position on the channel BeWo cells were found on the membrane area. Perfusion was continued 
for another 24 hours.  
 
As shown in Figure 20, most of the HUVEC cells remained close to the edge. The GFP 
fluorescence showed lighter spots on the image that were not confirmed as cells. During the 
Figure 20: Fluorescent image showing both HUVEC and BeWo cells inside the 
channels after 72hours of medium perfusion. (t=96hours). 
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perfusion, at least a small amount of medium could be transferred through the membrane. This 
small portion might be increased by the time. After 72 hours of medium perfusion (96 hours in 
total with the adhesion time), this medium might mix with the other channel’s medium with the 
result of conflicting data. The perfusion was then continued for only 12 more hours.  
After 84 hours of medium perfusion in total, the chip was again sent for fluorescent 
imaging. As shown in Figure 21, it became more difficult to identify the HUVEC cells on the 
top channel, but BeWo cells were somewhat visible in the bottom channel. A lack of cells and 
difficulty to take fluorescent imaging lead to stopping the perfusion after 84 hours of medium 
perfusion, 108 hours in total.  
Figure 21: Fluorescent image showing both HUVEC and BeWo cells inside the 
channels after 84 hours of medium perfusion. (t=108hours). 
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6.2 TEER measurements  
 
6.2.1 Experimental method 
As described in Chapter 5, Ag/AgCl electrodes were inserted to the inlet of the top 
channel and the outlet of the bottom channel. The reason for using Ag/AgCl electrodes was 
because Ag/AgCl electrodes will measure the voltage while Ag electrodes will pass the current 1. 
Resistance across two points was taken for empty chips and chips with cells on both sides of the 
membrane. Equation 6 (in Chapter 5) was used to calculate the Apparent TEER in Ohms-m2. 
TEER values were taken every 12 hours or six hours depending on the trial. A graph was created 
using calculated Apparent TEER values (Ohms-m2) vs. time (hours), as shown in Figure 22.  
Figure 22: Calculated Apparent TEER using resistance measured as 
described in Chapter 5, as a function of time. Three graphs represent 
three different trials as indicated in the legend.  
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TEER values measured in an ideal system were expected to be increased by the time due to cell 
growth. Higher cell numbers would result in higher cell coverage across the cell culture surface 
(membrane in this experiment). With higher cell coverage, the number of tight junctions will 
increase. It was found that even a small percentage difference of cell coverage could cause about 
80% lower TEER values compared to cell coverage at 100% 2. This can be identified from 
Figure 22. Based on the discussion in Section 6.1.2, cell coverage was gradually decreased 
compared to the beginning of the experiment.   
In Transwell systems, HUVEC cells remain in monolayers, but this is completely 
different in organ-on-chip devices. As Odijk et al.2 explained from their experiment, after 72 
hours of performance in their chip device, cells started to transform to a villi-like structure from 
the cells’ original monolayer structure. This will limit the space in the channels and result in a 
higher value for top channel resistance.  Another major issue that occurred during the TEER 
experiment was that fungus started growing in channels. As described earlier, this fungus could 
block the channel, resulting in an increase of the channel resistance.  
Also, using Ag/AgCl electrodes could cause many other problems. When Ag/AgCl 
electrodes are inserted into the chip, they release silver ions.3 The resistance then measured from 
the multimeter includes errors due to the toxicity of silver ions in the medium.2 Resistance is also 
temperature dependent; TEER values calculated from values measured from the multimeter also 
contained errors due to a temperature effect.  
 
6.2.2 Theoretical method  
Using the theoretical model, two different TEER values were calculated. This was due to 
a system conflict with the experimental model. The theoretical model is designed to have only 
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one cell layer on one side while the other side is perfused with the same culture medium used for 
the cell layer. Two values were calculated as 48 Ωcm2 and 111.4 Ωcm2 by assuming HUVEC 
and BeWo cells were cultured on one side of the channel, respectively. The calculated values 
were much lower compared to TEER values obtained from Transwell cultures (HUVEC = 
207Ωcm2 and BeWo = 160 Ωcm2 ).4,5 As discussed earlier, TEER values measured in chip 
devices are different from TEER values obtained from Transwell cultures. The theoretical model 
needs to be modified to have two different cell types for this design. This can be simply done by 
separating the membrane resistance into two different sections. Assuming MT and MB are newly 
inserted parameters for the circuit, representing top membrane and bottom membranes, 
respectively, 𝑅𝑀𝑇  𝑎𝑛𝑑 𝑅𝑀𝐵  can be separately calculated and the modified equation for RMX can 
be achieved.  
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CHAPTER 7 
CONCLUSION  
 
7.1 Conclusion 
In conclusion, the placenta-on-a-chip device was successfully designed for the 
engineering aspect of microfluidics. Chips were fabricated with PMMA milling and PDMS soft 
lithography techniques. PDMS chips were chosen for their ability to withstand lower thickness 
and for manufacturing simplicity. Cultured cells were injected onto the chips and successfully 
attached to the membrane. Cells were maintained long-term outside the incubator even with low 
cell densities inside the channels. Chips were able to be sent for fluorescent imaging without 
disassembling connecting tubes. It was discovered that, after 12 hours of cell adhesion, HUVEC 
cells were attached to the membrane, but after BeWo cells were injected and the chip kept for 
another 12 hours, most of the HUVEC cells were unattached. The 12 hour period of the cell 
adhesion period needs to be decreased. Alternatively, if BeWo cells take 12 hours to attach, 
perfusion for HUVEC cells should be started during the BeWo adhesion period. Also, it was 
discovered that imperfect alignment of channels during fabrication resulted in holding the cells 
close to walls, but this was mainly due to insufficient cell adhesion. Choosing a decent flow rate 
for the perfusion is important. Higher flow rates may result in forcing too much shear stress on 
the cells and lower flow rates may keep the same medium on cells for a longer time. Future work 
should be focused on increasing cell adhesion, perfecting channel alignment, and establishing 
suitable flow rates.  
For TEER measurements, the proposed theoretical method was not able to provide 
accurate TEER values, as it was designed to represent one cell layer on one channel and medium 
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perfusion on the other channel. This method needs to be redesigned to represent current 
functions of the chip. Results with errors can be reduced, but some of the parameters are hard to 
control (i.e. the temperature effect). The only option to reduce the temperature effect is by 
accounting for errors due to temperature in the calculation. It was also discovered that removing 
connecting tubes and inserting Ag/AgCl electrodes to the inlet/outlet resulted in contamination. 
Two parallel experiments run with identical conditions, with and without measuring TEER, 
showed more contamination on the chip used for TEER measurements. The air bubbles that 
occurred inside the channels also resulted in errors, as the lack of medium in the channel may 
cause lower conductivity through the channel. Another problem discovered during the 
experimental method was that to study the TEER values as a function of time, required removing 
the connecting tubing, which caused the air bubbles occurring inside the channels that are 
difficult to remove. The only option was faster perfusion, which resulted in higher shear stress on 
cells, thereby forcing them to detach.     
 
7.2 Future work 
The following sections discuss some future work planned/needed to complete in the 
future.  
 
7.2.1 Placenta-on-a-chip 
For future work, various cell adhesion times can be considered. Changing the cell 
adhesion time may significantly affect the percent of cell confluency on the membrane. The flow 
rate is also a parameter to change, as higher and lower flow rates may result in cell detachment. 
Another concept for increasing the cell adhesion can be to make the membrane more adhesive. 
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This can be achieved by adding an extra ECM (extracellular matrix) layers such as fibronectin. 
After successfully culturing cell layers on both sides, the chip can tested in long-term 
maintenance. While in maintenance, various tests can be run on the system to verify the 
functionality of the chip to analyze similar physiological functions of placental barrier. A glucose 
test is a widely used method to analyze how the placental barrier functions. EBM-2 and F-12 
mediums containing two different concentrations of glucose can be introduced to each channel. 
After some perfusion time, the output should be collected and a glucose monitoring test  
performed to see how well the barrier (membrane) functions similar to the real (in vivo) system. 
As a final goal, protein expression markers can be used to monitor transfer efficiency as well as 
to determine how similarly it represents the functions of the systems in vivo. Proteins such as 
Cadherin, type 1 transmembrane protein, provide more information on cell adhesion, as they are 
part of the adherence junction to bond cells in the tissues.    
 
7.2.2 TEER measurements  
As previous studies show, TEER is temperature dependent and the temperature effect 
needs to be accounted for in the measurements 1. It is important to create a chip with confluent 
cell layers, because small errors in cell confluency can result in higher errors on TEER values. A 
more suitable way of inserting electrodes into the inlet/outlet of the chip needs to be found, as 
inserting electrodes frequently resulted in contamination. The theoretical method needs to be 
modified relevant to match the system with two cell types. TEER values for HUVEC cells and 
BeWo cells in Transwell cultures need to be verified, as the literature shows different values 
depending on different conditions and cell type.  
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